Join experts Jonathan Mizrah, a medical oncologist at Ochsner Health specializing in HCC treatment, Lingling Du, who focuses on HCC trials, Adam Burgoyne from UCSD discussing immunotherapy communication, and interventional radiologist Zachary Berman on an insightful exploration of advanced liver cancer treatments. They discuss the promising role of combination therapies, particularly TACE with immunotherapy, and dive into groundbreaking clinical trial results. Simplifying complex mechanisms, they emphasize the importance of personalized treatment strategies and ongoing patient care.

In this engaging discussion, medical oncologists Adam Burgoyne and Lingling Du, alongside interventional radiologists Kirema Garcia-Reyes and Zachary Berman, tackle the complexities of hepatocellular carcinoma (HCC) treatment. They explore the 'grey zone' in treatment goals, emphasizing the importance of performance status and comprehensive liver function assessments. The guests share insights on navigating advanced liver disease, the role of immunotherapy, and the critical need for multidisciplinary collaboration to optimize patient outcomes.